Navigation Links
Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
Date:4/17/2008

Berlin, Germany: The first study to investigate the effects of chemotherapy on metastatic breast cancer in women with the BRCA1 or BRCA2 gene mutation has shown that standard chemotherapy works better in these patients than in women without the BRCA1/2 mutation.

The authors of a study presented today (Thursday) at the 6th European Breast Cancer Conference (EBCC-6) in Berlin found that women with BRCA2-associated breast cancer had a significantly higher response rate, a longer time without the disease progressing, and a longer overall survival when treated with anthracycline-based regimens than did women with sporadic breast cancers that were not associated with BRCA1/2.

Women with BRCA1-associated breast cancer also did better than women with sporadic breast cancer, but the rates were not statistically significant.

Researchers at the Daniel den Hoed Cancer Centre/Erasmus Medical Centre (Rotterdam, The Netherlands) conducted the study. They matched 112 women with BRCA1-associated metastatic cancer and 29 women with BRCA2-associated metastatic cancer with 141 women with sporadic breast cancers. The women had been treated with anthracycline-based or taxane-based regimens, CMF (cyclophosphamide, methotrexate and fluorouracil 5FU) or other chemotherapy regimens.

BRCA2 women had a higher response rate to chemotherapy (89% versus 50%), a longer progression-free survival (nearly a third better) and a longer overall survival (47% better) than did women with sporadic cancers. When the researchers looked more closely at the type of chemotherapy the women had received, they found that the improved progression-free survival mainly occurred in patients on anthracyclines and disappeared for those treated with CMF.

The lead author of the study, Dr Mieke Kriege, an epidemiologist and project researcher at the Rotterdam Family Cancer Clinic, said: It is difficult to make firm conclusions about response to different treatments from our results so far, but it does seem that the higher sensitivity to treatment by BRCA2-associated patients is especially caused by the anthracycline regimen.

The project leader, Professor Jan Klijn, medical oncologist and chairman of the Rotterdam Family Cancer Clinic, said: Our findings show that various standard chemotherapy regimens are clinically effective in the treatment of metastatic BRCA1/2-associated breast cancer. The observation of the high efficacy of anthracycline-based regimens is especially reassuring. However, we would like to emphasise that larger, additional studies are urgently needed to investigate further newer regimens containing taxanes and platinum compounds.

Dr Kriege said: Currently, there are very few studies on the efficacy of chemotherapy in BRCA1/2-associated breast cancer mainly a few, very small studies with less than 44 patients in the neo-adjuvant setting. Our study is the only one in metastatic disease and, with 141 BRCA1/2 gene mutation carriers included, it is by far the largest study in the world.

The authors believe that an explanation of why chemotherapy seems to work better in BRCA1/2 breast cancers than in sporadic cancers is due to the lack of a working BRCA1/2 protein. Functional BRCA1 and BRCA2 proteins are involved in DNA repair, said Dr Kriege. Most chemotherapeutic agents are active by damaging DNA (especially anthracycline-based regimens). In BRCA1 and BRCA2 mutation carriers, who have no functional BRCA1 and BRCA2 proteins respectively, DNA repair after chemotherapy might be worse than in sporadic patients resulting in better treatment responses. Pre-clinical studies showed that BRCA1 and BRCA2 mutated cells are especially sensitive to chemotherapeutic agents that cause double-strand DNA breaks (such as anthracyclines and platinum).

The researchers now plan to investigate the effects of adjuvant and neo-adjuvant treatments in women with BRCA1/2-associated breast cancers, and to evaluate taxane and platinum therapies further.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Related biology news :

1. Minimum information standards -- all for 1 and 1 for all
2. CO2 emissions could violate EPA ocean-quality standards within decades
3. Positron emission tomography superior to standard evaluation tools in measuring treatment response
4. NIST, Army researchers pave the way for anthrax spore standards
5. UC health news: molecular pathway may predict chemotherapy effectiveness
6. A search for protection against chemotherapy cardiotoxicity
7. Rain forest protection works in Peru
8. MIT works toward safer gene therapy
9. IdentiPHI Re Launches SAFmodule Software to Secure Novell(R) Networks
10. IdentiPHI Re Launches SAFmodule Software to Secure Novell(R) Networks
11. Alternative food networks connect ethical producers and consumers and can lead to healthier eating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... ... 2016 , ... STACS DNA Inc., the sample tracking software company, today announced ... has joined STACS DNA as a Field Application Specialist. , “I am thrilled ... COO of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology: